Gastroenteropancreatic Neuroendocrine Neoplasms

[1]  S. Shrikhande,et al.  Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics , 2016, Nuclear medicine communications.

[2]  K. Togashi,et al.  Clinical efficacy of dual-phase scanning using (68)Ga-DOTATOC-PET/CT in the detection of neuroendocrine tumours. , 2016, Clinical radiology.

[3]  P. Herscovitch,et al.  Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  A. Tutuş,et al.  Combined imaging with 68Ga-DOTA-TATE and 18F-FDG PET/CT on the basis of volumetric parameters in neuroendocrine tumors , 2016, Nuclear medicine communications.

[5]  R. Hruban,et al.  Surgical and molecular pathology of pancreatic neoplasms , 2016, Diagnostic Pathology.

[6]  I. Virgolini,et al.  Current knowledge on the sensitivity of the 68Ga-somatostatin receptor positron emission tomography and the SUVmax reference range for management of pancreatic neuroendocrine tumours , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  E. Krenning,et al.  Nephrotoxicity after PRRT with 177Lu-DOTA-octreotate , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  E. Krenning,et al.  Radiolabeled Somatostatin Analogue Therapy Of Gastroenteropancreatic Cancer. , 2016, Seminars in nuclear medicine.

[9]  J. Berlin,et al.  Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors , 2016, The Journal of Nuclear Medicine.

[10]  P. Herscovitch,et al.  PET/CT comparing 68Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[11]  E. Kebebew,et al.  Total 18F-FDG PET/CT Metabolic Tumor Volume Is Associated With Postoperative Biochemical Response in Patients With Metastatic Pheochromocytomas and Paragangliomas , 2016, Annals of surgery.

[12]  I. Virgolini,et al.  Direct comparison of 68Ga-DOTA-TOC and 18F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[13]  E. Krenning,et al.  NETTER-1 Phase III: Progression-Free Survival, Radiographic Response, and Preliminary Overall Survival Results in Patients With Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate. , 2016, Clinical advances in hematology & oncology : H&O.

[14]  H. Mahajan,et al.  Ga-68 DOTANOC PET/CT imaging in detection of primary site in patients with metastatic neuroendocrine tumours of unknown origin and its impact on clinical decision making: experience from a tertiary care centre in India. , 2016, Journal of gastrointestinal oncology.

[15]  H. Sorbye,et al.  ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas , 2016, Neuroendocrinology.

[16]  A. Sundin,et al.  Imaging of Neuroendocrine Tumors. , 2016, Frontiers of hormone research.

[17]  O. Mundler,et al.  18F-DOPA PET/CT in the diagnosis and localization of persistent medullary thyroid carcinoma , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[18]  Elise M. Blanchet,et al.  18F-FLT PET/CT in the Evaluation of Pheochromocytomas and Paragangliomas: A Pilot Study , 2015, The Journal of Nuclear Medicine.

[19]  E. Krenning,et al.  Neoadjuvant Treatment of Nonfunctioning Pancreatic Neuroendocrine Tumors with [177Lu-DOTA0,Tyr3]Octreotate , 2015, The Journal of Nuclear Medicine.

[20]  Abhishek Kumar,et al.  Role of (18)F-DOPA PET/CT and (131)I-MIBG planar scintigraphy in evaluating patients with pheochromocytoma. , 2015, Hellenic journal of nuclear medicine.

[21]  P. Bachellier,et al.  Dynamic 18F-FDOPA PET Findings After Carbidopa Premedication in 2 Adult Patients With Insulinoma-Related Hyperinsulinemic Hypoglycemia. , 2015, Clinical Nuclear Medicine.

[22]  J. Mortensen,et al.  64Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with 111In-DTPA-Octreotide in 112 Patients , 2015, The Journal of Nuclear Medicine.

[23]  G. Watkins,et al.  Role of Gallium-68 DOTATOC PET-CT in Neuroendocrine Tumors with Unknown Primary Site , 2015 .

[24]  Michael Goodman,et al.  Calculation of the Ki67 index in pancreatic neuroendocrine tumors: a comparative analysis of four counting methodologies , 2015, Modern Pathology.

[25]  Elise M. Blanchet,et al.  Superiority of [68Ga]-DOTATATE PET/CT to Other Functional Imaging Modalities in the Localization of SDHB-Associated Metastatic Pheochromocytoma and Paraganglioma , 2015, Clinical Cancer Research.

[26]  P. Ruszniewski,et al.  Nuclear imaging of neuroendocrine tumors with unknown primary: why, when and how? , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[27]  R. Hicks,et al.  Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. , 2015, Radiographics : a review publication of the Radiological Society of North America, Inc.

[28]  V. Ambrosini,et al.  Current status of PET imaging of neuroendocrine tumours ([18F]FDOPA, [68Ga]tracers, [11C]/[18F]-HTP). , 2015, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[29]  N. Pavlidis,et al.  A mini review on cancer of unknown primary site: A clinical puzzle for the oncologists , 2014, Journal of advanced research.

[30]  S. Delorme,et al.  Medullary Thyroid Carcinoma: Imaging. , 2015, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[31]  I. Modlin,et al.  Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors. , 2015, Frontiers of hormone research.

[32]  Z. Hussein,et al.  Erratum to: Diagnostic Performance of 68Ga-DOTATATE PET/CT, 18F-FDG PET/CT and 131I-MIBG Scintigraphy in Mapping Metastatic Pheochromocytoma and Paraganglioma , 2015, Nuclear Medicine and Molecular Imaging.

[33]  A. Al-nahhas,et al.  Gallium-68 Dotatate PET/CT is superior to other imaging modalities in the detection of medullary carcinoma of the thyroid in the presence of high serum calcitonin. , 2015, Hellenic journal of nuclear medicine.

[34]  I. Steffen,et al.  Searching for primaries in patients with neuroendocrine tumors (NET) of unknown primary and clinically suspected NET: Evaluation of Ga-68 DOTATOC PET/CT and In-111 DTPA octreotide SPECT/CT , 2014, Radiology and oncology.

[35]  Rakesh Kumar,et al.  Recurrent malignant pheochromocytoma with unusual omental metastasis: 68Ga-DOTANOC PET/CT and 131I-MIBG SPECT/CT scintigraphy findings , 2014, Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India.

[36]  Dan Huang,et al.  (18)F-FDG PET/CT can be used to detect non-functioning pancreatic neuroendocrine tumors. , 2014, International journal of oncology.

[37]  N. Kalra,et al.  A systematic review of management of neuroendocrine tumors: An experience from a tertiary care centre from India , 2014 .

[38]  A. Mojtahedi,et al.  The value of (68)Ga-DOTATATE PET/CT in diagnosis and management of neuroendocrine tumors compared to current FDA approved imaging modalities: a review of literature. , 2014, American journal of nuclear medicine and molecular imaging.

[39]  S. Severi,et al.  Peptide receptor radionuclide therapy for advanced neuroendocrine tumors. , 2014, Thoracic surgery clinics.

[40]  M. Vatn,et al.  Survival and prognostic factors in well-differentiated pancreatic neuroendocrine tumors , 2014, Scandinavian journal of gastroenterology.

[41]  T. Holland-Letz,et al.  SUV of [68Ga]DOTATOC-PET/CT Predicts Response Probability of PRRT in Neuroendocrine Tumors , 2014, Molecular Imaging and Biology.

[42]  O. Schillaci.  18F-DOPA and Other Radiopharmaceuticals for Imaging Unknown Primary Neuroendocrine Tumors , 2014, The Journal of Nuclear Medicine.

[43]  P. Bachellier,et al.  18F-Fluorodihydroxyphenylalanine PET/CT in Patients with Neuroendocrine Tumors of Unknown Origin: Relation to Tumor Origin and Differentiation , 2014, The Journal of Nuclear Medicine.

[44]  W. Willinek,et al.  Predictors of Long-Term Outcome in Patients with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy with 177Lu-Octreotate , 2014, The Journal of Nuclear Medicine.

[45]  Mohid S. Khan,et al.  Combination of Cross-Sectional and Molecular Imaging Studies in the Localization of Gastroenteropancreatic Neuroendocrine Tumors , 2014, Neuroendocrinology.

[46]  W. Brenner,et al.  Detection of pancreatic neuroendocrine tumors (PNET) using semi-quantitative [68Ga]DOTATOC PET in combination with multiphase contrast-enhanced CT. , 2014, The Quarterly Journal of Nuclear Medicine and Molecular Imaging.

[47]  F. Beuschlein,et al.  Neuroendocrine tumor recurrence: diagnosis with 68Ga-DOTATATE PET/CT. , 2013, Radiology.

[48]  Rakesh Kumar,et al.  PET/CT imaging of neuroendocrine tumors with 68Gallium-labeled somatostatin analogues: An overview and single institutional experience from India , 2014, Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India.

[49]  R. Kumar,et al.  Diagnostic accuracy of 68Ga-DOTANOC PET/CT imaging in pheochromocytoma , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[50]  C. Charnsangavej,et al.  Current update on medullary thyroid carcinoma. , 2013, AJR. American journal of roentgenology.

[51]  P. Bhosale,et al.  Imaging features of carcinoid tumors of the gastrointestinal tract. , 2013, AJR. American journal of roentgenology.

[52]  F. Montravers,et al.  Diagnostic accuracy of [18F]DOPA PET and PET/CT in patients with neuroendocrine tumors: a meta-analysis , 2013, Clinical and Translational Imaging.

[53]  Mohid S. Khan,et al.  Circulating tumor cells as prognostic markers in neuroendocrine tumors. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  R. Salazar,et al.  Gastroenteropancreatic neuroendocrine tumors: diagnosis and treatment , 2013, Annals of gastroenterology.

[55]  L. Kachnic,et al.  PET/CT of cancer patients: part 1, pancreatic neoplasms. , 2012, AJR. American journal of roentgenology.

[56]  Santosh Gupta,et al.  Renal and hematological toxicity in patients of neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-DOTATATE. , 2012, Cancer biotherapy & radiopharmaceuticals.

[57]  M. Falconi,et al.  Neuroendocrine tumor disease: an evolving landscape. , 2012, Endocrine-related cancer.

[58]  K. Öberg,et al.  Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[59]  S. Holm,et al.  Clinical PET of Neuroendocrine Tumors Using 64Cu-DOTATATE: First-in-Humans Study , 2012, The Journal of Nuclear Medicine.

[60]  S. Lata,et al.  Prospective evaluation of 68Ga-DOTA-NOC PET-CT in patients with recurrent medullary thyroid carcinoma: comparison with 18F-FDG PET-CT , 2012, Nuclear medicine communications.

[61]  R. Hicks,et al.  Changing paradigms with molecular imaging of neuroendocrine tumors. , 2012, Discovery medicine.

[62]  D. Sahani,et al.  State-of-the-art PET/CT of the pancreas: current role and emerging indications. , 2012, Radiographics : a review publication of the Radiological Society of North America, Inc.

[63]  G. Treglia,et al.  Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 fluorodeoxyglucose positron emission tomography: a meta-analysis , 2012, Endocrine.

[64]  Run Yu,et al.  Ki-67 proliferative index predicts progression-free survival of patients with well-differentiated ileal neuroendocrine tumors. , 2012, Human pathology.

[65]  P. Castaldi,et al.  Role of PET/CT in the functional imaging of endocrine pancreatic tumors , 2012, Abdominal Imaging.

[66]  Abhishek Kumar,et al.  68Ga-DOTANOC PET/CT in Patients With Carcinoma of Unknown Primary of Neuroendocrine Origin , 2012, Clinical nuclear medicine.

[67]  K. Gulenchyn,et al.  PET/CT using 18F-FDOPA provides improved staging of carcinoid tumor patients in a Canadian setting , 2012, Nuclear medicine communications.

[68]  P. Castaldi,et al.  Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis , 2012, Endocrine.

[69]  G. Åkerström,et al.  PET-Guided Surgery — High Correlation between Positron Emission Tomography with 11C-5-Hydroxytryptophane (5-HTP) and Surgical Findings in Abdominal Neuroendocrine Tumours , 2012, Cancers.

[70]  C. Compton,et al.  Exocrine and Endocrine Pancreas , 2012 .

[71]  B. Kos-Kudła,et al.  The value of the Ki-67 proliferation marker as a prognostic factor in gastroenteropancreatic neuroendocrine tumours. , 2012, Endokrynologia Polska.

[72]  P. Castaldi,et al.  Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[73]  Abhishek Kumar,et al.  Gallium-68-DOTA-NOC PET/CT of patients with gastroenteropancreatic neuroendocrine tumors: a prospective single-center study. , 2011, AJR. American journal of roentgenology.

[74]  P. Garg,et al.  Role of 68Ga-DOTATOC PET-CT in the diagnosis and staging of pancreatic neuroendocrine tumours , 2011, European Radiology.

[75]  V. Ambrosini,et al.  Incidence of Increased 68Ga-DOTANOC Uptake in the Pancreatic Head in a Large Series of Extrapancreatic NET Patients Studied with Sequential PET/CT , 2011, The Journal of Nuclear Medicine.

[76]  R. Buchert,et al.  Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[77]  D. Visvikis,et al.  Distribution pattern of 68Ga-DOTATATE in disease-free patients , 2010, Nuclear medicine communications.

[78]  P. Cumming,et al.  68Ga-DOTATATE PET/CT for the Early Prediction of Response to Somatostatin Receptor–Mediated Radionuclide Therapy in Patients with Well-Differentiated Neuroendocrine Tumors , 2010, The Journal of Nuclear Medicine.

[79]  R. Jensen,et al.  NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. , 2010, Pancreas.

[80]  I. Kayani,et al.  The Role of 68Ga-DOTATATE PET in Patients with Neuroendocrine Tumors and Negative or Equivocal Findings on 111In-DTPA-Octreotide Scintigraphy , 2010, Journal of Nuclear Medicine.

[81]  J. Mortensen,et al.  Functional Imaging of Neuroendocrine Tumors: A Head-to-Head Comparison of Somatostatin Receptor Scintigraphy, 123I-MIBG Scintigraphy, and 18F-FDG PET , 2010, Journal of Nuclear Medicine.

[82]  E. Krenning,et al.  Salvage Therapy with 177Lu-Octreotate in Patients with Bronchial and Gastroenteropancreatic Neuroendocrine Tumors , 2010, Journal of Nuclear Medicine.

[83]  Raffaele Pezzilli,et al.  Standardized Uptake Values of 68Ga-DOTANOC PET: A Promising Prognostic Tool in Neuroendocrine Tumors , 2010, Journal of Nuclear Medicine.

[84]  E. Baudin,et al.  Daily Oral Everolimus Activity in Patients with Metastatic Pancreatic Neuroendocrine Tumors after Failure of Cytotoxic Chemotherapy: A Phase II Trial , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[85]  Marion de Jong,et al.  Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. , 2010, Endocrine-related cancer.

[86]  J. Carrasquillo,et al.  Use of 6‐[18F]‐fluorodopamine positron emission tomography (PET) as first‐line investigation for the diagnosis and localization of non‐metastatic and metastatic phaeochromocytoma (PHEO) , 2009, Clinical endocrinology.

[87]  A. Barlier,et al.  18F-FDG Avidity of Pheochromocytomas and Paragangliomas: A New Molecular Imaging Signature? , 2009, Journal of Nuclear Medicine.

[88]  Yun Yen,et al.  NCCN clinical practice guidelines in oncology: hepatobiliary cancers. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[89]  J. Carrasquillo,et al.  Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. , 2009, The Journal of clinical endocrinology and metabolism.

[90]  V. Ambrosini,et al.  Detection of unknown primary neuroendocrine tumours (CUP-NET) using 68Ga-DOTA-NOC receptor PET/CT , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[91]  I. Kayani,et al.  Comparison of 68Ga-DOTATATE and 18F-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[92]  H. Dralle,et al.  The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT , 2009, European Radiology.

[93]  Manal M. Hassan,et al.  Risk factors associated with neuroendocrine tumors: A U.S.‐based case–control study , 2008, International journal of cancer.

[94]  Manal M. Hassan,et al.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[95]  A. Groves,et al.  Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga‐DOTATATE (DOTA‐DPhe1,Tyr3‐octreotate) and 18F‐FDG , 2008, Cancer.

[96]  M. Farnell,et al.  Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors. , 2008, Endocrine-related cancer.

[97]  E. D. de Vries,et al.  Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[98]  S. Houry,et al.  Tomographie par émission de positons au (18 F)fluorodésoxyglucose dans l'évaluation initiale des tumeurs du pancréas , 2008 .

[99]  C. Ko,et al.  Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors. , 2007, Journal of the American College of Surgeons.

[100]  Stefano Fanti,et al.  18F-DOPA PET and PET/CT , 2007, Journal of Nuclear Medicine.

[101]  Douglas B. Evans,et al.  Population-Based Study of Islet Cell Carcinoma , 2007, Annals of Surgical Oncology.

[102]  S. Larson,et al.  Diagnostic Accuracy of 18F-FDG PET in Restaging Patients with Medullary Thyroid Carcinoma and Elevated Calcitonin Levels , 2007, Journal of Nuclear Medicine.

[103]  E. D. de Vries,et al.  Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study. , 2006, The Lancet. Oncology.

[104]  M. Bergström,et al.  Whole-Body 11C-5-Hydroxytryptophan Positron Emission Tomography as a Universal Imaging Technique for Neuroendocrine Tumors : Comparison with Somatostatin Receptor Scintigraphy and Computed Tomography , 2005 .

[105]  M. Bergström,et al.  Developments in PET for the detection of endocrine tumours. , 2005, Best practice & research. Clinical endocrinology & metabolism.

[106]  B. Taal,et al.  Metastatic carcinoid tumors: a clinical review. , 2005, The oncologist.

[107]  Y. Morioka,et al.  Clinical pathology of endocrine tumors of the pancreas , 1991, Digestive Diseases and Sciences.

[108]  J. Reubi,et al.  68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5 , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[109]  H. Amthauer,et al.  Retrospective digital image fusion of multidetector CT and 18F-FDG PET: clinical value in pancreatic lesions--a prospective study with 104 patients. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[110]  M. Bergström,et al.  PET in the Diagnosis of Neuroendocrine Tumors , 2004, Annals of the New York Academy of Sciences.

[111]  S. Lamberts,et al.  Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours. , 2003, Endocrine-related cancer.

[112]  H. Lehnert,et al.  Somatostatin receptor subtypes in human pheochromocytoma: subcellular expression pattern and functional relevance for octreotide scintigraphy. , 2003, The Journal of clinical endocrinology and metabolism.

[113]  M. Kalra,et al.  Correlation of positron emission tomography and CT in evaluating pancreatic tumors: technical and clinical implications. , 2003, AJR. American journal of roentgenology.

[114]  P. Silverman,et al.  Diagnosis, staging, and surveillance of pancreatic cancer. , 2003, AJR. American journal of roentgenology.

[115]  I. Modlin,et al.  A 5‐decade analysis of 13,715 carcinoid tumors , 2003, Cancer.

[116]  M. Blaufox,et al.  The role of positron emission tomography in gastrointestinal imaging. , 2002, Gastroenterology clinics of North America.

[117]  H. Neumann,et al.  Pheochromocytomas: detection with 18F DOPA whole body PET--initial results.. , 2002, Radiology.

[118]  P. Ágoston,et al.  18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[119]  E. Nitzsche,et al.  Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors. , 2001, Radiology.

[120]  F. Pattou,et al.  Endocrine tumors of the pancreas , 2001 .

[121]  D. Finkelstein,et al.  Prognosis and survival in patients with gastrointestinal tract carcinoid tumors. , 1999, Annals of surgery.

[122]  E. Krenning,et al.  The use of somatostatin receptor scintigraphy in the differential diagnosis of pancreatic duct cancers and islet cell tumors. , 1996, Annals of surgery.

[123]  T. Ponchon,et al.  Pancreas and ampulla of Vater. , 1994, Clinics in diagnostic ultrasound.

[124]  S. Winawer.  Tests for pancreatic cancer , 1978 .